An anxiolytic composition includes a synergistic combination of one or more of an extract of magnolia, an extract of phellodendron, an L-theanine, a whey protein composition, and/or an s-adenosylmethionine (SAMe).

An anxiolytic composition includes a synergistic combination of one or more of an extract of magnolia, an extract of phellodendron, an L-theanine, a whey protein composition, and/or an s-adenosylmethionine (SAMe).

Compositions for treating a sleep disorder or modifying or improving the sleep-wake cycle in a subject are disclosed herein. In some examples, the composition can comprise one or more sleep promoting active agents, one or more sleep quality active agents, one or more sleep recovery active agents, and optionally one or more next day active agents. The composition can provide an immediate burst release of the one or more sleep promoting active agents, a delayed burst or delayed sustained release of the one or more sleep quality active agents, a delayed burst or delayed sustained release of the one or more sleep recovery active agents, and a delayed burnt or delayed sustained release of the one or more next day active agents. The composition can be provided as a daily oral uni-dosage form. Methods of making and using the compositions are also provided.

Compositions for treating a sleep disorder or modifying or improving the sleep-wake cycle in a subject are disclosed herein. In some examples, the composition can comprise one or more sleep promoting active agents, one or more sleep quality active agents, one or more sleep recovery active agents, and optionally one or more next day active agents. The composition can provide an immediate burst release of the one or more sleep promoting active agents, a delayed burst or delayed sustained release of the one or more sleep quality active agents, a delayed burst or delayed sustained release of the one or more sleep recovery active agents, and a delayed burnt or delayed sustained release of the one or more next day active agents. The composition can be provided as a daily oral uni-dosage form. Methods of making and using the compositions are also provided.

Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.

Aspects of the invention relate to compositions comprising two or more live bacterial strains for topical administration to the skin, wherein the two or more live bacterial strains are Propionibacterium acnes (P. acnes) bacterial strains, and methods for use.

Aspects of the invention relate to compositions comprising two or more live bacterial strains for topical administration to the skin, wherein the two or more live bacterial strains are Propionibacterium acnes (P. acnes) bacterial strains, and methods for use.

The present invention provides a protein-containing composition that can be ingested without reducing the intake, and without placing a burden on the kidney and the liver. Provided is a protein-containing composition for enteral intake, the composition including at least 81% by mass micellar casein with respect to the total protein, which composition is for ingestion by a subject requiring suppression or prevention of a decline(s) in renal function and/or liver function.

The present invention provides a protein-containing composition that can be ingested without reducing the intake, and without placing a burden on the kidney and the liver. Provided is a protein-containing composition for enteral intake, the composition including at least 81% by mass micellar casein with respect to the total protein, which composition is for ingestion by a subject requiring suppression or prevention of a decline(s) in renal function and/or liver function.

The disclosure provides a method of improving the cognitive function of an animal by providing a composition containing beta-casein, wherein at least 75% by weight of the beta-casein is a beta-casein variant that does not produce BCM-7 on digestion in the gut of the animal.